BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, December 9, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sector
See today's BioWorld Science
Home
» Elima Therapeutics patents new tyrosine kinase inhibitors for idiopathic pulmonary fibrosis
To read the full story,
subscribe
or
sign in
.
Respiratory
Elima Therapeutics patents new tyrosine kinase inhibitors for idiopathic pulmonary fibrosis
June 21, 2024
Elima Therapeutics Inc. has disclosed tyrosine kinase inhibitors reported to be useful for the treatment of idiopathic pulmonary fibrosis.
BioWorld Science
Respiratory
Patents